Gilead’s Kite nabs Carl June spinout Tmunity after neurotox kills patients, forcing reorg — and a rethink – Endpoints News

Madrigal Pharmaceuticals says its NASH drug, resmetirom, has met its early endpoints in a Phase III trial, marking a major success in a field littered with failures in recent years. Now, the company plans to submit for accelerated approval in the first half of next year, CEO Paul Friedman said in a statement.

The biotech’s stock $MDGL was up over 200% in pre-market trading, eclipsing the $200 mark. It had closed at just under $64 on Friday.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,700+ biopharma pros reading Endpoints daily — and it’s free.


Leave a Comment

Your email address will not be published. Required fields are marked *